Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacopo Giuliani

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
Recenti Progressi in Medicina|June 21, 2017
Jacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|January 19, 2016
Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled TrialsJacopo Giuliani, Andrea Bonetti
Journal of Medical Virology|November 20, 2020
COVID-19 and cancer: A clear change not only in daily clinical practice but also in clinical research managementJacopo Giuliani, Andrea Bonetti
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (<i>EGFR</i>)-mutations in first-line for advanced non-small cell lung cancerJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|April 20, 2016
The development of hypertension in metastatic colorectal cancer patients treated with aflibercept: the role of systolic and diastolic blood pressure before starting treatmentJacopo Giuliani, Andrea Bonetti
Journal of Gastrointestinal Cancer|August 5, 2016
The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical TrialsJacopo Giuliani, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research|June 27, 2017
Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costsJacopo Giuliani, Andrea Bonetti
The Lancet Regional Health. Europe|September 24, 2021
Implications of drugs with rebate in EuropeAndrea Bonetti, Jacopo Giuliani
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 24, 2021
Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancerJacopo Giuliani, Francesco Fiorica
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 2, 2019
FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic CancerJacopo Giuliani, Andrea Bonetti
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
Recenti Progressi in Medicina|June 21, 2017
Jacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|January 19, 2016
Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled TrialsJacopo Giuliani, Andrea Bonetti
Journal of Medical Virology|November 20, 2020
COVID-19 and cancer: A clear change not only in daily clinical practice but also in clinical research managementJacopo Giuliani, Andrea Bonetti
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (<i>EGFR</i>)-mutations in first-line for advanced non-small cell lung cancerJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|April 20, 2016
The development of hypertension in metastatic colorectal cancer patients treated with aflibercept: the role of systolic and diastolic blood pressure before starting treatmentJacopo Giuliani, Andrea Bonetti
Journal of Gastrointestinal Cancer|August 5, 2016
The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical TrialsJacopo Giuliani, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research|June 27, 2017
Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costsJacopo Giuliani, Andrea Bonetti
The Lancet Regional Health. Europe|September 24, 2021
Implications of drugs with rebate in EuropeAndrea Bonetti, Jacopo Giuliani
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 24, 2021
Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancerJacopo Giuliani, Francesco Fiorica
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 2, 2019
FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic CancerJacopo Giuliani, Andrea Bonetti
Pageof 14